hCTLA-4(BALB/c)
Nomenclature
BALB/cAnSmoc-Ctla4em1(hCTLA4) Smoc
Cat. NO.
NM-HU-190078
Strain State
Repository Live
Gene Summary
Gene Symbol
CTLA4
Model Description
Validation Data
Figure 1. Expression of CTLA4 in the activated spleen lymphocytes of homozygous humanized CTLA4 BALB/c KI mice is detected by FACS.
Fig2. In vivo validation of homozygous BALB/c-hCTLA4 mice. The homozygous BALB/c-hCTLA4 mice were inoculated with CT26 cells, and randomly assigned to different groups (n=7) when the tumor grew to a volume of 100 mm3. A combinatorial treatment of anti-hCTLA4 antibody Yervoy and entinostat (ENT; a class I HDAC inhibitor) demonstrated a noticeable efficacy improvement compared to the same dose of single agent (A) without affecting the animal body weight (B).
Fig3. In vivo validation of homozygous BALB/c-hCTLA4 mice. The homozygous BALB/c-hCTLA4 mice were inoculated with H22 cells, and randomly assigned to different groups (n=7) when the tumor grew to a volume of 100 mm3. Treatment of anti-hCTLA4 antibody Yervoy and Teremelimumab can effectively control tumor growth in BALB/c-hCTLA4 mice (A) without affecting the animal body weight (B).
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
